Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Johnson and Johnson
AstraZeneca
Boehringer Ingelheim
Colorcon

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

KEPIVANCE Drug Profile

See Plans and Pricing

« Back to Dashboard

Summary for Tradename: KEPIVANCE
Patents:44
Applicants:1
BLAs:1
Suppliers: see list1
Recent Clinical Trials: See clinical trials for KEPIVANCE
Recent Clinical Trials for KEPIVANCE

Identify potential brand extensions & biosimilar entrants

SponsorPhase
City of Hope Medical CenterPhase 1
Spectrum Pharmaceuticals, IncPhase 1/Phase 2
AstraZenecaPhase 1/Phase 2

See all KEPIVANCE clinical trials

Pharmacology for KEPIVANCE

Company Disclosures: US Patents for KEPIVANCE

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Biovitrum Ab KEPIVANCE palifermin INJECTABLE; INJECTION 125103 001 2004-12-15   Start Trial Chiron Corporation (Emeryville, CA) 2039-03-29 RX company
Biovitrum Ab KEPIVANCE palifermin INJECTABLE; INJECTION 125103 001 2004-12-15   Start Trial Amgen Inc. (Thousand Oaks, CA) 2015-09-29 RX company
Biovitrum Ab KEPIVANCE palifermin INJECTABLE; INJECTION 125103 001 2004-12-15   Start Trial Amgen Inc. (Thousand Oaks, CA) 2015-10-20 RX company
Biovitrum Ab KEPIVANCE palifermin INJECTABLE; INJECTION 125103 001 2004-12-15   Start Trial The United States as represented by the Department of Health and Human (N/A) (Washington, DC) 2019-07-16 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for KEPIVANCE

These patents were identified by searching patent claims

Supplementary Protection Certificates for KEPIVANCE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
SZ 4/2006 Austria   Start Trial PRODUCT NAME: PALIFERMIN
4/2006 Austria   Start Trial PRODUCT NAME: PALIFERMIN; REGISTRATION NO/DATE: EU/1/05/314/001 20051025
SZ 15/2006 Austria   Start Trial PRODUCT NAME: PALIFERMIN
300230 Netherlands   Start Trial 300230, 20100130, EXPIRES: 20150129
SPC/GB06/015 United Kingdom   Start Trial PRODUCT NAME: PALIFERMIN; REGISTERED: UK EU/1/05/314/001 20051025
06C0016 France   Start Trial PRODUCT NAME: PALIFERMINE; REGISTRATION NO/DATE IN FRANCE: EU/1/05/314/001 DU 20051025; REGISTRATION NO/DATE AT EEC: EU/1/05/314/001 DU 20051025
C300230 Netherlands   Start Trial PRODUCT NAME: PALIFERMIN; REGISTRATION NO/DATE: EU/1/05/314/001 20051025
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Moodys
Mallinckrodt
Merck
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.